Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 14, 2005; 11(26): 4013-4017
Published online Jul 14, 2005. doi: 10.3748/wjg.v11.i26.4013
Published online Jul 14, 2005. doi: 10.3748/wjg.v11.i26.4013
Table 1 Patients’ characteristics before therapy
NYT | Control | P | |
Age (yr) | 46.3 ± 14.3 | 54.9 ± 10.3 | 0.113 |
Gender (M/F) | 9/1 | 8/5 | 0.123 |
Body weight (kg) | 65.2 ± 9.8 | 60.6 ± 9.1 | 0.291 |
ALT (U/L) | 74.9 ± 38.2 | 58.1 ± 25.1 | 0.457 |
Hb ( g/dL) | 14.3 ± 1.4 | 14.0 ± 1.6 | 0.709 |
HCVRNA (kIU/mL) | 553.5 ± 315.0 | 637.6 ± 314.0 | 0.673 |
HCV serotype (1/2) | 8/2 | 9/4 | 0.377 |
Table 2 Virological and biochemical results
NYT (%) | Control (%) | P | |
Enrolled cases | 10 | 13 | |
Normal ALT at the end of therapy | 7 (70.0) | 6 (46.2) | 0.253 |
Negative HCVRNA at the end of therapy | 8 (80.0) | 7 (53.8) | 0.192 |
Normal ALT 6 mo after therapy | 8 (80.0) | 4 (30.8) | 0.489 |
Negative HCVRNA 6 mo after therapy | 4 (40.0) | 4 (30.8) | 0.645 |
Table 3 Hematological and immunological results
NYT | Control | P | |
Max△RBC (× 103) | 868 ± 474 | 1.244 ± 419 | 0.178 |
Max△Hb (g/dL) | 2.59 ± 1.10 | 3.71 ± 0.97 | 0.026 |
min Hb (g/dL) | 11.66 ± 1.78 | 10.10 ± 1.08 | 0.079 |
WBC (wk 24) | 3 444 ± 1731 | 3 204 ± 1143 | 0.894 |
Plts (wk 24, × 104) | 14.69 ± 5.52 | 12.77 ± 4.22 | 0.709 |
Th1 (wk 4, %) | 27.29 ± 11.6 | 30.20 ± 8.66 | 0.480 |
Th2 (wk 4, %) | 2.77 ± 1.06 | 2.30 ± 1.09 | 0.232 |
Th1/Th2 (wk 4) | 10.89 ± 5.68 | 15.48 ± 6.87 | 0.130 |
GP×[wk 4, nmol/(min·mL)] | 76.41 ± 31.79 | 78.96 ± 31.96 | 0.522 |
Table 4 Multiple regression analysis
Variable | Parameter estimate | Standard error | P |
Intercept | -1.61742 | 1.12391 | 0.1707 |
NYT administration | 1.47645 | 0.43746 | 0.0042 |
Serum creatinine (wk 0) | -3.05400 | 1.57891 | 0.0722 |
Table 5 Comparison of NYT and other drugs which were reported to be effective for RBV-induced anemia
Action | Mechanisms | Indication for anemia in health | Form | Adverse reactions | Daily cost | |
insurance system of Japan | (yen) | |||||
NYT | Promotion of erythropoiesis, | Activation of immature | Anemia in | Granule | Abdominal discomfort | 227.7 |
protection of erythrocytic | erythroid cells, | general, | (frequency unknown) | |||
membrane, improvement of | antioxidant effect | |||||
erythrocytic deformability | ||||||
EPA | Increase in erythrocyte | Increase in EPA content in | None | Capsule | Jaundice, gynecomastia | 353.4 |
deformability | erythrocytic membrane | (frequency unknown), | ||||
phospholipids | hemorrhagic tendency, | |||||
liver injury (< 0.1%) | ||||||
EPO | Increase in erythropoiesis | Stimulation of stem cell | Renal anemia | Vial for | Thromboembolism, | 1643 |
differentiation to | injection | cerebral hemorrhage, | (750 IU) | |||
erythroid cells | shock (frequency unknown), | |||||
high blood pressure, liver | ||||||
injury (0.1-< 5%) |
- Citation: Motoo Y, Mouri H, Ohtsubo K, Yamaguchi Y, Watanabe H, Sawabu N. Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: A randomized controlled trial. World J Gastroenterol 2005; 11(26): 4013-4017
- URL: https://www.wjgnet.com/1007-9327/full/v11/i26/4013.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i26.4013